NCT06137144 - AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies. | Biotech Hunter

Enrollment

110

Participants

Timeline

Start Date

January 23, 2024

Primary Completion Date

May 8, 2026

Study Completion Date

May 8, 2026

Conditions

LymphomaNon-HodgkinHodgkin Lymphoma

Interventions

DRUG

AZD3470

AZD3470 is a novel, potent and selective, second-generation, Methylthioadenosine (MTA)-selective, small molecule inhibitor of PRMT5.

Trial Locations (20)

6009

RECRUITING

Research Site, Nedlands

15100

RECRUITING

Research Site, Alessandria

19104

RECRUITING

Research Site, Philadelphia

20141

RECRUITING

Research Site, Milan

28041

RECRUITING

Research Site, Madrid

30322

WITHDRAWN

Research Site, Atlanta

33136

RECRUITING

Research Site, Miami

40138

RECRUITING

Research Site, Bologna

50937

RECRUITING

Research Site, Cologne

59000

RECRUITING

Research Site, Lille

69310

RECRUITING

Research Site, Pierre-Bénite

77030

RECRUITING

Research Site, Houston

94010

RECRUITING

Research Site, Créteil

94805

RECRUITING

Research Site, Villejuif

02215

RECRUITING

Research Site, Boston

03080

RECRUITING

Research Site, Seoul

06351

RECRUITING

Research Site, Seoul

08908

RECRUITING

Research Site, L'Hospitalet de Llobregat

M20 4BX

RECRUITING

Research Site, Manchester

OX3 7LE

RECRUITING

Research Site, Oxford